Top Page
Zymeworks
(NASDAQ:ZYME)
Zymeworks (ZYME) vs. SPDR S&P 500 ETF (SPY)
Zymeworks Business Overview & Revenue Model
Zymeworks Earnings Call Summary
Zymeworks Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 122.87M | 76.30M | 76.01M | 412.48M | 26.68M | 38.95M |
| Gross Profit | 116.52M | 65.11M | -66.98M | 203.78M | -172.86M | -131.94M |
| EBITDA | -60.80M | -105.42M | -120.70M | 147.24M | -206.09M | -177.17M |
| Net Income | -73.67M | -122.69M | -118.67M | 124.34M | -211.84M | -180.55M |
Balance Sheet | ||||||
| Total Assets | 408.38M | 463.09M | 580.88M | 648.73M | 389.13M | 538.38M |
| Cash, Cash Equivalents and Short-Term Investments | 281.38M | 225.78M | 374.33M | 492.23M | 252.61M | 426.35M |
| Total Debt | 18.68M | 18.51M | 26.72M | 28.11M | 32.33M | 8.64M |
| Total Liabilities | 73.88M | 124.32M | 116.07M | 155.77M | 140.04M | 128.45M |
| Stockholders Equity | 334.51M | 338.77M | 464.81M | 492.96M | 249.09M | 409.92M |
Cash Flow | ||||||
| Free Cash Flow | -68.51B | -113.11M | -122.38M | 130.98M | -205.74M | -157.67M |
| Operating Cash Flow | -68.51B | -110.04M | -118.30M | 144.11M | -192.45M | -151.40M |
| Investing Cash Flow | 86.97M | 38.76M | -207.25M | -53.85M | 144.60M | -43.44M |
| Financing Cash Flow | -20.99M | -20.45M | 81.85M | 108.58M | 8.01M | 308.98M |
Zymeworks Technical Analysis
Zymeworks Risk Analysis
Zymeworks Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $1.34B | ― | -19.89% | ― | 95.94% | 35.69% | |
54 Neutral | $1.79B | ― | -50.34% | ― | 6.07% | -2.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $817.27M | ― | -65.35% | ― | 48.32% | -1.91% | |
43 Neutral | $1.17B | ― | -43.82% | ― | ― | -7.33% | |
42 Neutral | $647.86M | ― | -73.44% | ― | ― | -1.07% | |
33 Underperform | $1.45B | ― | -109.12% | ― | ― | 7.58% |
Zymeworks Corporate Events
Zymeworks Inc. announced it will report its third quarter 2025 financial results on November 6, 2025, followed by a conference call and webcast to discuss the results and provide a corporate update. This announcement highlights the company’s ongoing efforts to advance its pipeline of therapeutic candidates and maintain transparency with stakeholders, potentially impacting its market position and investor confidence.
The most recent analyst rating on (ZYME) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks announced the presentation of preliminary data from its Phase 1 trial of ZW191, an antibody-drug conjugate targeting folate receptor-⍺, at an international cancer conference. The data highlights ZW191’s potential in treating advanced solid tumors, including ovarian and lung cancers, and supports the company’s broader ADC portfolio. This development underscores Zymeworks’ commitment to advancing differentiated therapies for challenging cancers, potentially impacting its market positioning and offering new treatment options for patients.
The most recent analyst rating on (ZYME) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. has appointed Dr. Adam Schayowitz as Acting Chief Development Officer to further advance its portfolio of therapeutic candidates and strengthen strategic partnerships. Dr. Schayowitz, with extensive experience in oncology drug development, will work closely with Zymeworks’ R&D and Business Development teams to accelerate the company’s efforts in bringing innovative therapies to market, enhancing its industry positioning and potential impact on patients worldwide.
The most recent analyst rating on (ZYME) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. has announced the discontinuation of the clinical development of ZW171, a T cell engager targeting mesothelin-driven cancers, due to an unfavorable benefit-risk profile observed during the Phase 1 trial. Despite this setback, Zymeworks remains committed to advancing its broader product pipeline, including the ongoing trials for ZW191 and the upcoming trials for ZW251 and ZW209, reflecting the company’s disciplined approach to resource allocation and its focus on candidates with the greatest potential impact.
The most recent analyst rating on (ZYME) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. announced its participation in several upcoming investor conferences, where management will engage in one-on-one meetings and fireside chats. These events provide an opportunity for Zymeworks to showcase its advancements and strategic initiatives, potentially enhancing its visibility and investor relations within the biotechnology sector.
The most recent analyst rating on (ZYME) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
The recent earnings call for Zymeworks showcased a robust financial performance, marked by a significant increase in revenue and a return to net income. The company’s strategic partnerships and clinical advancements have reinforced a positive business momentum, although there are some concerns regarding supply chain planning and the timing of clinical readouts.
Zymeworks Inc. has announced the appointment of Greg Ciongoli and Robert E. Landry to its Board of Directors, enhancing its leadership with their extensive financial and strategic expertise. This move comes as Zymeworks advances its development programs and regulatory approvals, positioning the company for significant growth and value creation in the biotechnology sector. The appointments are expected to support Zymeworks’ long-term strategy and commitment to delivering innovative therapies to patients globally.
The most recent analyst rating on (ZYME) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. is a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for challenging diseases such as cancer, inflammation, and autoimmune conditions. In its second-quarter 2025 earnings report, Zymeworks announced significant progress in its strategic partnerships and drug development pipeline, alongside a notable increase in revenue. The company reported $48.7 million in revenue for the quarter, driven by milestone achievements and existing partnerships, marking a substantial increase from the previous year. Zymeworks’ cash resources stood at $333.4 million, providing a runway into the second half of 2027. Key developments include the FDA clearance for ZW251 and international approvals for zanidatamab, enhancing patient access globally. The company also highlighted its strategic focus on leveraging its Azymetric platform and partnerships to drive long-term growth. Looking ahead, Zymeworks remains committed to advancing its R&D programs and strategic partnerships to enhance shareholder value and improve patient outcomes.
On August 7, 2025, Zymeworks Inc. reported its second quarter financial results, highlighting a revenue of $48.7 million and a cash reserve of $333.4 million as of June 30, 2025. The company announced the FDA clearance of an IND application for ZW251, with first-in-human studies planned for 2025, and noted international approvals for zanidatamab in biliary tract cancer. These developments, along with strategic partnerships, are expected to enhance Zymeworks’ long-term business strategy and financial stability.
The most recent analyst rating on (ZYME) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks has announced the FDA clearance of its investigational new drug application for ZW251, a novel glypican-3-targeted antibody-drug conjugate (ADC) designed to treat hepatocellular carcinoma (HCC). This marks the second ADC from Zymeworks’ pipeline to progress into clinical development, highlighting the company’s confidence in its proprietary topoisomerase 1 inhibitor payload. Preclinical studies have shown promising anti-tumor activity and tolerability, with Phase 1 clinical trials expected to begin in 2025. The advancement of ZW251 underscores Zymeworks’ commitment to developing innovative treatments for challenging diseases and could potentially improve the standard of care for HCC patients.
The most recent analyst rating on (ZYME) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.